It is worthy to note that p53 expression increased upon combination treatment, which is consistent with our recent finding that VERU-111 could inhibit tumor growth and migration in cervical cancer cells by promoting DNA damage response mediated by p53 (Kashyap et al., 2020). Here, TP53 is linked to cervical cancer.